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Abstract 
Background: Pancreatic cancer is currently one of the leading causes of cancer deaths without any effective thera‑
pies. Mir‑145 has been found to be tumor‑suppressive in various types of cancers. The aim of this study is to investi‑
gate the role of miR‑145 in pancreatic cancer cells and explore its underlying mechanism.
Methods: Quantitative real time PCR was used to determine the expression level of miR‑145 and angiopoietin‑2 
(Ang‑2) mNRA, and the expression level of Ang‑2 protein was measured by western blotting. The anti‑cancer activities 
of miR‑145 were tested both in in vitro by using cell invasion and colony formation assay and in vivo by using xeno‑
graft assay. The direct action of miR‑145 on Ang‑2 was predicted by TargetScan and confirmed by luciferase report 
assay. The vascularization of xenografts were performed by immunohistochemical analysis.
Results: The expression level of miR‑145 was significantly lower and the expression levels of Ang‑2 mRNA and pro‑
tein was significantly higher in the more aggressive pancreatic cancer cells (MiaPaCa‑2 and Panc‑1) when compared 
to that in BxPC3 cells. Overexpression of miR‑145 in the BxPC3, MiaPaCa‑2 and Panc‑1 cells suppressed the cell inva‑
sion and colony formation ability, and the expression level of Ang‑2 protein in MiaPaCa‑2 and Panc‑1 cells was also 
suppressed after pre‑miR‑145 transfection. Intratumoral delivery of miR‑145 inhibited the growth of pancreatic cancer 
xenografts and angiogenesis in vivo, and also suppressed the expression level of angiopoietin‑2 protein. Luciferase 
report assay showed that Ang‑2 is a direct target of miR‑145, and down‑regulation of angiopoietin‑2 by treatment 
with Ang‑2 siRNA in the BxPC3, MiaPaCa‑2 and Panc‑1 cells suppressed cell invasion and colony formation ability. The 
reverse transcription PCR results also showed that Tie1 and Tie2 were expressed in BxPC3, MiaPaCa‑2 and Panc‑1 cells.
Conclusion: MiR‑145 functions as a tumor suppressor in pancreatic cancer cells by targeting Ang‑2 for translation 
repression and thus suppresses pancreatic cancer cell invasion and growth, which suggests that restoring of miR‑145 
may be a potential therapeutic target for pancreatic cancer.
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Background
Pancreatic cancer was the fourth leading cause of can-
cer-related deaths and more than 45,000 new cases 
were estimated in 2013 [1]. Recent studies showed that 
tumor suppressor loci were mutated or down-regulated 
in human pancreatic tumors, which accelerated tumor 
progression and resulted in invasive and metastatic 
malignancies [2]. However, the role of tumor suppressors 
in pancreatic tumors are still largely unknown.
MicroRNAs (miRNAs) are a family of non-coding 
RNAs with a short length of 19–25 nucleotides. MiRNAs 
functioned as oncogene or tumour suppressor by bind-
ing to the 3′-untranslated region (UTR) of target genes to 
regulate their expression [3–5]. MiRNAs play an impor-
tant role in many physiological and pathological pro-
cesses, including in almost all aspects of cancer biology, 
such as cell proliferation, apoptosis, invasion/metastasis, 
and angiogenesis [6]. Studies have shown that miR-145 
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has important implications in etiology, treatment and 
pathogenesis of cancer, including pancreatic cancers. 
Previous studies demonstrated the tumor suppressive 
role of miR-145 in caners, in which miR-145 suppressed 
liver and head and neck cancer cell invasion by target-
ing on ADAM metallopeptidase domain 17 [7, 8]. MiR-
145 was also reported to repress pluripotency in human 
embryonic stem cells via regulating the expression of 
octamer-binding transcription factor 4, sex determining 
region Y-box 2 and Kruppel-like factor 4 [9]. Moreover, 
in many other types of cancers, miR-145 and its direct 
target were also reported, for example, miR-145 directly 
targets AKT3 in thyroid cancer [10], and miR-145 also 
targets Mucin 1, cell surface associated in metastatic 
breast cancer [11], p70S6K1 in colon cancer [12], insulin-
like growth factor receptor 1 in human bladder cancer 
cells [13], c-Myc in non-small cell lung cancer [14] and 
the transcription factor signal transducer and activator of 
transcription 1 in colon cancer [15]. Recently, Khan et al. 
[16] reported that miR-145 targeted Mucin 13, cell sur-
face associated to suppress growth and invasion of pan-
creatic cancer cells.
Angiopoietin-2 (Ang-2) is the ligand for an endothelial 
cell-specific tyrosine kinase receptor, and plays a key role 
in angiogenesis and tumor progression [17, 18]. Previ-
ous study reported that Ang-2 played a significant role in 
pancreatic carcinoma angiogenesis, and knockdown of 
Ang-2 induced anti-angiogenesis effect both in vitro and 
in  vivo [19, 20]. Up to date, there is no evidence show-
ing that expression of Ang-2 is linked with miRNAs in 
pancreatic cancers. In the present study, by using bioin-
formatics analytic tool (Targetscan), the 3′UTR of Ang-2 
gene was found to be a target of miR-145. Here, we docu-
mented the tumor suppressive role of miR-145 in pan-
creatic cell lines. Subsequent analyses further established 




The human pancreatic cancer cells (MiaPaCa-2 and 
Panc-1) were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Life Technologies, Inc., Gaithers-
burg, MD) and BxPC-3 cells were cultured in RPMI-
1640 medium (Life Technologies, Inc., Gaithersburg, 
MD), and both medium were supplemented with 10  % 
FBS (Life Technologies, Inc.) and 100 units/ml penicillin 
and 100 units/ml streptomycin. The BxPC-3, MiaPaCa-2 
and Panc-1 cells were seeded to be 60–80 % confluent in 
6-well plates 24 h before the cells were transfected with 
30  pmol of either precursor of miR-145 (pre-miR-145; 
Ambion; P/N: AM17100, Product ID: PM11480) or 
scramble miRNA (Pre-miR™ miRNA Precursor Negative 
Control #1, P/N: AM17110); and angiopoietin-2 siRNA 
(siAng-2) or scramble (RiboBio, Guangzhou) using the 
Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, 
CA) according to the manufacturer’s instructions. Forty-
eight hours after transfection, cells were processed for 
further experiments as described below.
In vitro invasion assay
The invasion assays in the pancreatic cancer cell lines 
were performed in a modified two-chamber assay. 
2 × 105 cells were seeded on the upper chamber of 6-well 
Transwell plates (Costar; Cambridge, MA) coated with 
Matrigel (Becton–Dickinson, Heidelberg, Germany) 
diluted at a 1:2 ratio with medium and incubated for 
24 h. The lower chamber was filled with DMEM contain-
ing 10 % FBS. After 24 h incubation, cells on the upper 
side of the membrane were wiped off and the membrane 
was fixed with 4 % paraformaldehyde and 0.25 % glutar-
aldehyde. Cells on the lower side of the membrane were 
stained with 0.5 % methylene blue in 50 % methanol and 
invaded cells were counted under a microscope. All inva-
sion assays were done in triplicate.
Quantitative real‑time PCR (qRT‑PCR) analysis
Total RNA was extracted from cultured cells using TRI-
zol® reagent (Invitrogen). DNaseI-treated RNA was used 
for first strand cDNA synthesis using M-MLV reverse 
transcriptase (Promega) and oligo (dT) 15 according 
to the manufacture’s protocols and 1  μl cDNA samples 
were used for conventional PCR amplifications. QRT-
PCR analysis was performed in a real-time PCR system 
(StepOne, Applied Biosystems) and the expression lev-
els of Ang-2 were normalized to GAPDH determined 
by a SYBR Green-based comparative cycle threshold CT 
method. Real-time PCR primers were: Ang-2-F: 5′-AGA 
TTT TGG ACC AGA CCA GTG A-3′, Ang-2-R: 5′-GGA 
TGA TGT GCT TGT CTT CCA T-3′; GAPDH-F: 
5′-TGT GGG CAT CAA TGG ATT TGG-3′, GAPDH-R: 
5′-ACA CCA TGT ATT CCG GGT CAA T-3′; miR-
145-F: 5′-AAG GGA GTC CAG TTT TCC CAG GAA 
TCC-3′, miR-145-R: 5′-GTC GTA TCC AGT GCA GGG 
TCC GAG GTA TTC GCA CTG GAT ACG AC-3′; U6-F: 
5′-CTC GCT TCG GCA GCA CA-3′, U6-R: 5′-AAC 
GCT TCA CGA ATT TGC GT-3′.
Western blotting
The expression of Ang-2 was measured in pancreatic 
cancer cell lines (BxPC-3, MiaPaCa-2 and Panc-1) or 
tumor tissue by western blotting. Protein extraction 
was performed using the extraction buffer contain-
ing 10  mM Tris HCl (pH 7.5), 2  M urea, 2  mM EDTA, 
2 mM EGTA, and protease inhibitors. Thirty micrograms 
of protein were loaded onto SDS–polyacrylamide gels, 
Page 3 of 9Wang et al. Cancer Cell Int  (2016) 16:65 
size fractionated on SDS-PAGE gels, and transferred to 
a nitrocellulose membrane using the semidry technique. 
The membranes were blocked with 5  % milk powder in 
TBST for 1  h. Specific monoclonal anti-Ang-2 (ab8452) 
and monoclonal anti-β-actin (ab3280) primary antibod-
ies (Abcam Biotechnology, Cambridge, MA, USA) were 
used, and HRP conjugated immunoglobulin was used as 
a secondary antibody (Jackson ImmunoResearch Labo-
ratories). West Pico Chemiluminescent (Pierce) was used 
as the substrate to visualize protein bands, which were 
quantified using densitometry image analysis software 
(Image Master VDS; Pharmacia Biotech). Normalization 
was made against β-actin expression.
ELISA
Ang-2 concentrations in BxPC3, MiaPaCa-2 and Panc-1 
cell culture supernatant were determined after trans-
fection with pre-miR-145 for 48  h. Measurements were 
made with a commercially available enzyme-linked 
immunosorbent assay (ELISA) (R&D Systems, Minneap-
olis, USA) according to the manufacturers’ instructions.
Soft agar assay
Colony formation and cell growth rate in soft agar were 
tested by plating 2.5  ×  104 of BxPC3, MiaPaCa-2 and 
Panc-1 cells transfected with scramble or pre-miR-145 in 
0.4 ml DMEM, supplemented with 100 units/ml penicil-
lin, 100 g/ml streptomycin, 100 g/ml amphotericin B, 3 % 
FBS, and 0.3  % low melting temperature agarose (Sea-
plaque) in 12-well plates (6 wells for each) coated with 
0.8  ml 0.6  % low melting temperature agarose. Platelet-
derived growth factor-bb (50  ng/ml) was added to half 
of the wells of each type of transfected cells. Colony for-
mation was monitored for 5 days in 37 °C incubator, and 
colony number was counted under a microscope.
In vivo study
Female nude mice (4–6 weeks, 18–20 g) were purchased 
from the Model Animal Research Center of Nanjing Uni-
versity. 5  ×  106 of Panc-1 cells (resuspended in 100  μl 
saline) were injected subcutaneously into the right flank 
of each mouse. Tumor volumes were determined every 
5 days after injection as described previously [21]. Mice 
with xenografts volume lager than 500 mm3 were treated 
with intratumoral injection of saline twice a week (saline 
group), scramble (saline plus scramble group) or pre-
miR-145 (saline plus pre-miR-145 group) for 4  weeks. 
Each treatment group has eight animals. At the end of 
the experiment, mice were sacrificed and tumors were 
dissected for immunohistochemistry and western blot 
analysis. All the animal study was carried out in strict 
accordance with Institutional Animal Ethics Care and 
Use Committee of the Jiangsu Cancer Hospital (approved 
number 21040608). All surgery was performed under 
sodium pentobarbital anesthesia, and efforts were made 
to minimize suffering.
Immunohistochemistry
Immunohistochemical analysis of vascularization was 
performed using the analySIS system and the monoclo-
nal antibody against Factor VIII (ab41186, abcam Bio-
technology, Cambridge, MA, USA). Briefly, 5  µm thick 
FFPE sections were cut, placed on slides coated with 
3-triethoxysilylpropylamine (Sigma, St. Louis, Missouri, 
USA), and then fixed overnight at 37  °C. After depar-
affinization in xylene and rehydrating through graded 
alcohols, the slides were incubated in H2O2 to block 
endogenous peroxidase activity. Then sections were 
incubated with primary monoclonal antibody against 
Factor VIII (5  µg/ml) at 4  °C overnight. After over-
night incubation, the sections were washed with PBS 
for 5  min ×  3 times, and the sections were then incu-
bated with biotinylated goat anti-rabbit immunoglobulin 
(dilution 1:300; Vector Laboratories, Burlingame, Cali-
fornia, USA). The peroxidase activity was visualized by 
3,3′-diaminobenzidine tetrahydrochloride. Hematoxylin 
was used as a counter stain.
The degree of vascularization was measured by the 
average number of Factor VIII-positive microvessels 
in three different areas at 200-fold magnification and 
recorded as microvessel density (MVD). Briefly, the Fac-
tor VIII stained sections were initially scanned at low 
power (100-fold magnification) and the areas having 
the highest number of microvessels were selected. Sub-
sequently, microvessel counting was performed in three 
different areas at 200-fold magnification and the mean 
value was used for further analysis. Any clearly stained 
endothelial cells or cell clusters were considered as a 
single countable microvessel, regarding the presence of 
lumen and large vessels were automatically excluded 
from the analysis.
Constructs and luciferase assay
To determine whether Ang-2 is a downstream media-
tor of miR-145, the entire human Ang-2 3′-untranslated 
region (UTR) segment was amplified by PCR using 
mouse genomic DNA as a template. The PCR products 
were inserted into the p-MIR-report plasmid (Ambion). 
For luciferase reporter assay, 1  μg of firefly luciferase 
reporter plasmid, 0.5  μg of β-galactosidase expression 
vector (Ambion), and equal amount (200  pmol) of pre-
miR-145 or scrambled negative control miRNA were 
transfected into cells in 6-well plates. The β-galactosidase 
vector was used as a transfection control. Twenty-four 
hours after transfection, cells were assayed using lucif-
erase assay kits (Promega).
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Statistics
All results were expressed as mean ± SEM from at least 
three independent experiments. Significance analysis of 
normal distributed data were performed using two-tail 
Student’s t test, One-Way ANOVA, or Two-way ANOVA, 
as appropriate and P values of less than 0.05 were consid-
ered statistically significant.
Results
The expression of miR‑145 is reduced in more 
aggressive pancreatic cancer cell lines and accompanied 
with increased expression of Ang‑2
To elucidate whether the expression level of miR-145 
are correlated with the cell invasion ability of pancreatic 
cancer, three well-studied human pancreatic cancer cell 
lines, BxPC3, MiaPaCa-2 and Panc-1 were investigated in 
the present study. In vitro invasion assay results showed 
that MiaPaCa-2 and Panc-1 were more aggressive than 
BxPC3, and our qRT-PCR results demonstrated that the 
expression levels of miR-145 were lower in MiaPaCa-2 
and Panc-1 cells when compared to that in BxPC3 cells 
(Fig.  1a, b). Moreover, qRT-PCR and western blot-
ting analysis showed that the mRNA and protein levels 
of anigopoietin-2 were also found to be higher in both 
Panc-1 and MiaPaCa-2 when compared to that in less 
invasive BxPC3 cells (Fig.  1d). These findings indicates 
that the expression of miR-145 and Ang-2 might be cor-
related with the invasive capacity of pancreatic cancer 
cells.
MiR‑145 suppressed cell invasion via decreasing the 
expression of Ang‑2 in vitro
The role of miR-145 in pancreatic cancer cells was further 
investigated by using miR-145 gain-of-function study in 
the human pancreatic cancer cell lines. The results shown 
that ectopic expressed miR-145 in BxPC3, MiaPaCa-2 
and Panc-1 cells (Fig.  2a) significantly decreased thecell 
invasion and colony formation ability (Fig. 2b, c). Moreo-
ver, western blotting results showed that lower protein 
expression levels of Ang-2 were found in miR-145-over-
expressing Panc-1 and MiaPaCa-2 cells, but not in BxPC3 
cells when compared with control group transfected with 
scramble miRNA (Fig. 2d). In addition, down-regulation 
of Ang-2 were also found in the supernatant of culture 
media of miR-145-overexpressing Panc-1 and MiaPaCa-2 
cells, but not in BxPC3 cells (Fig.  2e). These findings 
Fig. 1 Down‑regulation of miR‑145 accompanied with up‑regulation of Ang‑2 in more aggressive pancreatic cancer cells. a, b The invasion ability 
of BxPC3, MiaPaca‑2 and Panc‑1 cells was measured by in vitro invasion assay; c the expression level of miR‑145 in BxPC3, MiaPaca‑2 and Panc‑1 
cells was measured by qRT‑PCR; d the expression levels of Ang‑2 mRNA and protein in BxPC3, MiaPaca‑2 and Panc‑1 cells were measured by qRT‑
PCR and western blotting, respectively. Data represents the mean ± SEM, n = 3, significant differences compared to BxPC3 group are indicated as 
*P < 0.05, **P < 0.01, ***P < 0.001 (one‑way ANOVA followed by Bonferroni test)
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implicated that down-regulation of miR-145 might 
enhance the in  vitro cell invasion and colony formation 
of pancreatic cancer cells via enhancing the expression of 
Ang-2.
MiR‑145 inhibited tumor growth and angiogenesis in vivo
To further elucidate the significance of miR-145 in the 
tumor growth capacity of pancreatic cancer in  vivo, 
miR-145 were delivered intratumorally in xenografts 
formed by relative more invasive pancreatic cancer cell 
line Panc-1. The results showed that treatment of miR-
145 significantly inhibited the growth of xenografts 
formed by Panc-1 when compared to that treated with 
saline or vector control (Fig.  3a, b). Moreover, MiR-
145 treatment also decreased microvessels density as 
well as expression levels of Ang-2 in xenografts when 
compared to that treated with saline or vector control 
(Fig. 3c, d). These findings indicate that miR-145 might 
inhibit cell growth of pancreatic cancer cells via its 
anti-angiogenesis effect mediated by down-regulation 
of Ang-2.
MiR‑145 directly regulated the expression of Ang‑2 
in pancreatic cancer cells
To further elucidate whether miR-145 could directly reg-
ulate the expression of Ang-2 in pancreatic cancer cells, 
the effect of miR-145 on the luciferase activity of Ang-2 
gene 3′-UTR were investigated. The luciferase report 
assay demonstrated that transiently transfected with 
pre-miR-145 decreased the luciferase activity of Ang-2 
3′-UTR in BxPC3, MiaPaCa-2 and Panc-1 cells (Fig. 4a). 
Transfection with siAng-2 in BxPC3, MiaPaCa-2 and 
Panc-1 cells significantly decreased cell invasion and 
colony formation ability (Fig. 4b, c). Further reverse tran-
scription PCR results demonstrated that Tie1 and Tie2 
are presented in BxPC3, MiaPaCa-2 and Panc-1 cells. 
These findings indicate that miR-145 might regulate the 
expression of Ang-2 in pancreatic cancer cells directly.
Fig. 2 MiR‑145 suppressed cell invasion and colony formation via decreasing the expression of Ang‑2 in vitro. a Ectopic expression of miR‑145 
increased expression levels of miR‑145 in BxPC3, MiaPaCa‑2 and Panc‑1 cells; b, c ectopic expression of miR‑145 decreased the cell invasion and 
colony formation ability of BxPC3, MiaPaCa‑2 and Panc‑1 cells; d overexpression of miR‑145 decreased Ang‑2 protein levels in MiaPaCa‑2 and Panc‑1 
cells but not in BxPC3 cells; e the expression of Ang‑2 was lower in the supernatant of culture media of miR‑145 over‑expressing MiaPaCa‑2 and 
Panc‑1 cells when compared to control groups. Data represents the mean ± SEM, n = 3, significant differences between groups are indicated as 
*P < 0.05, **P < 0.01, ***P < 0.001 (unpaired t test)
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Discussion
Antiangiogenic therapy targeting the vascular endothe-
lial growth factor (VEGF) pathway has been considered 
as a standard cancer therapy strategy in the past decade 
[22, 23]. Ang-2-targeting therapies are now regarded as 
second-generation antiangiogenic drugs that combine 
Fig. 3 MiR‑145 inhibited tumor growth and angiogenesis in vivo. a, b MiR‑145 significantly inhibited the growth of xenografts formed by Panc‑1 
when compared with saline or vector control group; c miR‑145 treatment decreased microvessels density in xenografts isolated 45 days after 
subcutaneous injection when compared to saline or vector control group; d the expression levels of Ang‑2 in xenografts treated with miR‑145 were 
lower than that in the saline or vector control group. Data represents the mean ± SEM, n = 8, significant differences between groups are indicated 
as ***P < 0.001 (one‑way ANOVA followed by Bonferroni test)
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with anti-VEGF to improve the hitherto limited clinical 
efficacy of established antiangiogenic therapy [24–26]. 
Recently, Ang-2 antibody treatment combines well with 
low-dose metronomic chemotherapy showed the effec-
tive anti-inflammatory and anti-angiogenic response 
of endothelial cells [27], provided a potential target of 
antiangiogenic drug development. We here reported that 
miR-145 suppressed the cell invasion via directly regulat-
ing the expression of Ang-2 in pancreatic cancer cells and 
ectopic expression of miR-145 inhibited tumor growth 
and angiogenesis in  vivo. This study not only provided 
the information that Ang-2 may involve in pancreatic 
cancer cell invasion for the first time, but also provided a 
new strategy to develop antiangiogenic drug by targeting 
on miR-145.
The role of miR-145 in cancer have been extensively 
studied in various types of cancers. Most of the studies 
were focused on effect of miR-145 on cancer cell prolif-
eration and metastasis. However, its role in tumor angio-
genesis remains poorly defined. One study demonstrated 
miR-145 inhibited tumor angiogenesis and growth by 
neuroblastoma RAS and VEGF in breast cancers [28]. 
The role of miR-145 on tumor angiogenesis is also found 
in osteosarcoma cells as well as colon cancer cells by tar-
geting on VEGF and p70S6K1, respectively [12, 29]. Our 
study was consistent with previous studies showing the 
tumor suppressive roles in pancreatic cancer.
In the present study, we demonstrated that miR-
145 suppressed cell invasion via directly regulating the 
expression of Ang-2 in pancreatic cancer. Ang-2 has 
been found to play an important role in angiogenesis 
and tumor progression. However, we also found that the 
mRNA expression level of Ang-2 in Panc-1 cells was sig-
nificantly higher than that in MiaPaCa-2 cells; though 
there was no significant difference in Ang-2 protein levels 
between MiaPaCa-2 and Panc-1 cells. The possible rea-
son could be that the difference of Ang-2 protein levels 
was very small and the semi-quantitative western blot-
ting assay was not sensitive enough to detect the signifi-
cant difference; and more sensitive assay be required in 
the future study. Recent study also showed that Ang-2 
mediated beta-1-integrin activation as promoter of 
endothelial destabilization by enhancing β1-integrin-
positive elongated matrix adhesions and actin stress 
fibers [30]. Because of complexity of Ang-2 signaling 
pathway, its role still requires further investigation [31]. 
Fig. 4 MiR‑145 directly regulated the expression of Ang‑2 in pancreatic cancer cells. a The effect of miR‑145 on the luciferase activity of Ang‑2 
promoter were measured, the luciferase activity of Ang‑2 promoter were all decreased in BxPC3, MiaPaCa‑2 and Panc‑1 cells; b, c down‑regulation 
of Ang‑2 by treatment with siAng‑2 decreased the invasion and colony formation ability of BxPC3, MiaPaCa‑2 and Panc‑1 cells; d the expression of 
Tie1 and Tie2 in BxPC3, MiaPaCa‑2 and Panc‑1 was determined by reverse transcription PCR. Data represents the mean ± SEM, n = 3, significant 
differences between groups are indicated as *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired t test)
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Based on literature research and bioinformatics analysis 
(TargetScan), Ang-2 was predicted to be a down-stream 
mediator of miR-145. The present study showed Ang-2 
is regulated by miR-145 in pancreatic cancer cells, which 
has been confirmed by examining the expressing levels of 
Ang-2 mRNA and protein as well as the luciferase report 
assay. As miR-145 have multiple targets, whether Ang-2 
being specific for pancreatic cancer cell proliferation and 
invasion is still questionable. In the future study, we may 
restore the expression levels of Ang-2 to investigate the 
specific role of Ang-2 on tumor progression in pancreatic 
cancer. In addition, Ang-2 exerting its effect by interact-
ing with Tie 1/2 receptor [32], but there is no evidence 
showing the existence of Tie 1/2 receptor in the pancre-
atic cancer cells. Therefore, it is necessary for us to deter-
mine the distribution and expression of these receptors 
in the future study, which may help us further understand 
the mechanistic action of Ang-2 in pancreatic cancer.
The study of miRNA-based therapies is still in its 
infancy. The first miRNA-based therapy specifically for 
cancer is using miRNA mimics or miRNA inhibitor, such 
as using synthetic miR-34a mimic loaded in liposomal 
nanoparticles to suppress liver cancer [33]. Till now, 
the most advanced miRNA trial involves use of anti-
miR-122 for hepatitis C therapy [34], which can reduce 
miR-122 expression by complementary binding to miR-
122 sequence to lock nucleic acid structure. Meanwhile, 
several studies have focused on small-molecule com-
pound’s modulation on microRNA expression. So far, 
the small-molecule modulators of miR-21, miR-122 and 
miR-34a have been identified with potent biologic activi-
ties [6, 35, 36].
In conclusion, our in vitro and in vivo studies suggest 
that miR-145 had a tumor suppressive effect on the pan-
creatic cancer cells. Therefore, miR-145 mimics or the 
small molecular modulators of miR-145 may provide the 
promising strategy to explore Ang-2 targeting antiangio-
genic drugs in the future.
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